Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SUAVE: Sequential Avelumab and Sunitinib in Metastatic RCC
NCT03035630Phase 2Withdrawn
- Start
- May 2017
- Primary completion
- Dec 2018
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of avelumab in clear cell renal cell carcinoma (ccRCC). Planned start May 2017; status: withdrawn.
02
Drugs
avelumab
03
Conditions
clear cell renal cell carcinoma (ccRCC)
Beyond the preview
Go deeper on NCT03035630.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03035630.